Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | XIAP | P98170 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7038704 | 0.88 | LMNA (0.53) | TP53LMNA | |
| SCHEMBL5764293 | 0.87 | DRD2 (0.53) | NPC1RAB9AL3MBTL1NPSR1 | |
| SCHEMBL7043244 | 0.86 | KDM4E (0.53) | LMNA | |
| SCHEMBL3208272 | 0.86 | NPC1 (0.54) | NPC1RAB9AL3MBTL1 | |
| SCHEMBL1000224 | 0.86 | NPC1 (0.54) | NPC1RAB9AL3MBTL1 | |
| SCHEMBL24582713 | 0.86 | NPC1 (0.54) | NPC1RAB9AL3MBTL1 | |
| SCHEMBL7038648 | 0.85 | KDM4E (0.62) | LMNA | |
| SCHEMBL12474768 | 0.83 | NPC1 (0.51) | NPC1RAB9AL3MBTL1TP53 | |
| SCHEMBL5763420 | 0.83 | NPC1 (0.53) | NPC1RAB9AL3MBTL1NPSR1 | |
| SCHEMBL7310845 | 0.82 | NPC1 (0.48) | NPC1RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030027743-A1 | Tripeptidylpeptidase inhibitors | INSERM | 2003-02-06 | — | — | US | disclosed |
| US-6403561-B1 | DISORDERS ASSOCIATED WITH THE INACTIVATION OR EXCESSIVE DEGRADATION OF CHOLECYSTOKININ; INHIBITING THE ENZYMATIC HYDROLYSIS OF CHOLECYSTOKININ 1-(2(S)-AMINOBUTYRYL)-2(S)-INDOLINECARBOXYLIC ACID | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2002-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027743-A1 | Tripeptidylpeptidase inhibitors | DPP4, DPP3, DPP9 | PTPN1 1367/4885NPC1 368/4885RAB9A 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.